Memo

To: CP-CTNet Colleagues

From: CP-CTNet Steering Committee

Date: March 31, 2022

Subject: Quarterly Steering Committee Information Dissemination

---

1. Publication Working Group

- The CP-CTNet Publication Guidelines were approved and will be emailed to CP-CTNet colleagues and will be posted to the CP-CTNet DMACC website under Resources - https://www.cp-ctnet-dmacc.org/public/program-resources/.

2. EDI Committee Update

- Subcommittees
  - EDI for Education
    - The committee plans on sending out a learning-needs survey to all the LAOs to be passed through to the AOs as well.
  - EDI in Clinical Trials
    - The committee is discussing best practices, improving the protocol template to address inclusion, how to improve recruitment strategies and will be directly addressing exclusion/inclusion criteria.
  - EDI in Staffing
    - Dr. Howard Bailey is polling CP-CTNet sites regarding EDI institutional policies and staffing.

3. Cross-Network Trial Update

- The trial INT21-05-01 received Approved on Hold status on 02.23.2022 and is awaiting FDA response on the IND. We should hear by 04.24.2022. The following are still pending: regulatory documents, SVAR approval, agent availability and study initiation visit.

4. Changes in Study PIs

- Reminder to LAOs to share all staffing changes with PIO, DMACC, and CP-CTNet leadership. An SOP is being developed to give guidance on this procedure.

5. LAO Oversight/Monitoring vs. DMACC Auditing

Cancer Prevention Clinical Trials Network (CP-CTNet)
Data Management, Auditing, and Coordinating Center (DMACC)
www.cp-ctnet-dmacc.org

Page 1 of 2

NCI Cancer Prevention Clinical Trials Network
A program of the National Cancer Institute of the National Institutes of Health

CP-CTNet DMACC
Cancer Prevention Clinical Trials Network
Data Management, Auditing, and Coordinating Center

- Discussions continue amongst CP-CTNet leadership, LAOs and DMACC. DMACC will develop tools to help LAOs with monitoring to include providing reports to the LAOs. SOP 03-03 LAO Oversight of AOs is in the process of being revised with input from DCP, DMACC and LAOs.

6. International Site GDPR Issues

- GDPR = General Data Protection Regulation - it is a privacy and security law in the European Union (EU) that is similar to HIPAA in the US. Though it was drafted and passed by the EU, it imposes obligations onto organizations anywhere, so long as they target or collect data related to people in the EU. The regulation was put into effect on May 25, 2018. This has implications on CP-CTNet trials that will include European sites. CP-CTNet may need to look into separate monitoring/auditing teams in Europe to cover trials conducted there.

7. Funding Opportunities

- Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) **https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-061.html**

- Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention and Control Clinical Trials Planning Grant (U34 Clinical Trials Optional) **https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-062.html**

- Clinical Scientist Award (R50) **https://grants.nih.gov/grants/guide/pa-files/PAR-21-306.html**

- Concept solicitation #11 will be released **04.20.2022** and due **06.20.2022**.

Cycle #	Steering Committee Date	Concept Solicitation Date	Concept Due Date
10	Jan. 28, 2022	Feb. 4, 2022	April 4, 2022
11	March 31, 2022	April 20, 2022	June 20, 2022
12	July 29, 2022	Aug. 5, 2022	Oct. 5, 2022
13	Oct. 28, 2022	Nov. 4, 2022	Jan. 9, 2023

- Next CP-CTNet Steering Committee Meeting: **07.29.2022 (in-person in Rockville, MD)**

Cancer Prevention Clinical Trials Network (CP-CTNet)
Data Management, Auditing, and Coordinating Center (DMACC)
www.cp-ctnet-dmacc.org

Page 2 of 2